Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer [PDF]
Clinical Cancer Research, 2021 AbstractChromosomal rearrangements of NTRK1–3 resulting in gene fusions (NTRK gene fusions) have been clinically validated as oncogenic drivers in a wide range of human cancers. Typically, NTRK gene fusions involve both inter- and intrachromosomal fusions of the 5′ regions of a variety of genes with the 3′ regions of NTRK genes leading to TRK fusion ...
Theodore W. Laetsch, David S. Hong
openaire +3 more sources
Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors
Clinical Pathology, 2023 Oncogenic neurotrophic tropomyosin receptor kinase gene fusions occur in less than 1% of common cancers. These mutations have emerged as new biomarkers in cancer genomic profiling with the approval of selective drugs against tropomyosin receptor kinase ...
Mariana Petaccia de Macedo +9 more
doaj +1 more source
NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
Frontiers in Oncology, 2022 Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer (NSCLC) with a frequency of approximately less than 1%.
Fangfang Liu +5 more
doaj +1 more source
gene amplification in patients with metastatic cancer [PDF]
Precision and Future Medicine, 2017 Purpose Neurotropic tropomyosin receptor kinase (NTRK) fusions have been identified in a variety of cancers, and tyrosine kinase inhibitors targeting the tropomyosin receptor kinase (TRK) receptor are currently in clinical trials. However, no reports are
Su Jin Lee +13 more
doaj +1 more source
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis. [PDF]
Cancers (Basel), 2020 Italiano A +15 more
europepmc +3 more sources
Frontiers in Physiology, 2021 A sedentary lifestyle is the top preventable cause of death and accounts for substantial socioeconomic costs to society. The rostral ventrolateral medulla regulates blood pressure under normal and pathophysiological states, and demonstrates inactivity ...
Bozena E. Fyk-Kolodziej +1 more
doaj +1 more source
Brain-Derived Neurotrophic Factor/Tropomyosin Receptor Kinase B Signaling Controls Excitability and Long-Term Depression in Oval Nucleus of the BNST. [PDF]
J Neurosci, 2021 Fiedler D +6 more
europepmc +3 more sources
Resolving the binding-kinase discrepancy in bacterial chemotaxis: A nonequilibrium allosteric model and the role of energy dissipation [PDF]
Proc. Natl. Acad. Sci. U.S.A. 120, e2303115120 (2023), 2023 The Escherichia coli chemotaxis signaling pathway has served as a model system for studying the adaptive sensing of environmental signals by large protein complexes. The chemoreceptors control the kinase activity of CheA in response to the extracellular ligand concentration and adapt across a wide concentration range by undergoing methylation and ...
arxiv +1 more source
The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII [PDF]
Journal of Experimental & Clinical Cancer Research, 2018 Oncogenes derived from the neurotrophin receptor tropomyosin-related kinase TrkA act as drivers in sub-populations of a wide-range of human cancers. This, combined with a recent report that both adult and childhood cancers driven by novel oncogenic TrkA chimeric-fusions exhibit profound, long-lived therapeutic responses to the Trk inhibitor ...
Farina, Antonietta Rosella +6 more
openaire +4 more sources
Modulation of Tropomyosin Receptor Kinase for the Treatment of Neurotrophin Diseases: Alzheimer's, Huntington's and Parkinson's. [PDF]
ACS Med Chem Lett, 2019 Kargbo RB.
europepmc +5 more sources